Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis

Vaccine

Volumn 26, Issue 46, 2008, Pages 5814-5821

  Yin, Ying ^a   Zhang, Jun ^a   Dong, Dayong ^a   Liu, Shuling ^a   Guo, Qiang ^a   Song, Xiaohong ^a   Li, Guanlin ^a   Fu, Ling ^a   Xu, Junjie ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Anthrax protective antigen; Anthrax vaccine; HBc particles; Neutralizing epitope

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTHRAX TOXIN; ANTHRAX VACCINE; EPITOPE; FREUND ADJUVANT; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN N144 PA LOOP2 PROTEIN; HEPATITIS B CORE ANTIGEN N144 PROTEIN; HYBRID PROTEIN; RECOMBINANT PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY SPECIFICITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL VIRULENCE; CHIMERA; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GUINEA PIG; HEPATITIS B VIRUS; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SERODIAGNOSIS; VIRUS LIKE AGENT; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; GUINEA PIGS; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; MUTANT CHIMERIC PROTEINS; NEUTRALIZATION TESTS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPORES, BACTERIAL; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS;

EID: 53649111582     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.031     Document Type: Article

References (51)

1. Mock M., Fouet A., and Anthrax. Annu Rev Microbiol 55 (2001) 647-671
2. Turnbull P.C. Introduction: anthrax history, disease and ecology. Curr Top Microbiol Immunol 271 (2002) 1-19
3. Mourez M. Anthrax toxins. Rev Physiol Biochem Pharmacol 152 (2004) 135-164
4. Young J.A., and Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 76 (2007) 243-265
5. Turnbull P.C. Anthrax vaccines: past, present and future. Vaccine 9 8 (1991) 533-539
6. Turnbull P.C. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr Opin Infect Dis 13 2 (2000) 113-120
7. Hambleton P., Carman J.A., and Melling J. Anthrax: the disease in relation to vaccines. Vaccine 2 2 (1984) 125-132
8. Pittman P.R., Gibbs P.H., Cannon T.L., and Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 20 5-6 (2001) 972-978
9. Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Friedlander A.M., et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281 18 (1999) 1735-1745
10. Surveillance for adverse events associated with anthrax vaccination-U.S. Department of Defense, 1998-2000. MMWR Morb Mortal Wkly Rep 2000;49(16):341-345.
11. Sato P.A., Reed R.J., Smith T.C., and Wang L. Monitoring anthrax vaccine safety in US military service members on active duty: surveillance of 1998 hospitalizations in temporal association with anthrax immunization. Vaccine 20 17-18 (2002) 2369-2374
12. Ferrari M.E., Hermanson G., and Rolland A. Development of anthrax DNA vaccines. Curr Opin Mol Ther 6 5 (2004) 506-512
13. Smith M.E., Koser M., Xiao S., Siler C., McGettigan J.P., Calkins C., et al. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 353 2 (2006) 344-356
14. Li Z.N., Mueller S.N., Ye L., Bu Z., Yang C., Ahmed R., et al. Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity. J Virol 79 15 (2005) 10003-10012
15. Iacono-Connors L.C., Welkos S.L., Ivins B.E., and Dalrymple J.M. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect Immun 59 6 (1991) 1961-1965
16. Tan Y., Hackett N.R., Boyer J.L., and Crystal R.G. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther 14 17 (2003) 1673-1682
17. Lee J.S., Hadjipanayis A.G., and Welkos S.L. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect Immun 71 3 (2003) 1491-1496
18. Galen J.E., Zhao L., Chinchilla M., Wang J.Y., Pasetti M.F., Green J., et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun 72 12 (2004) 7096-7106
19. Brey R.N. Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 57 9 (2005) 1266-1292
20. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., and Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature 385 6619 (1997) 833-838
21. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., et al. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 70 3 (2002) 1653-1656
22. Kasuya K., Boyer J.L., Tan Y., Alipui D.O., Hackett N.R., and Crystal R.G. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Mol Ther 11 2 (2005) 237-244
23. Maynard J.A., Maassen C.B., Leppla S.H., Brasky K., Patterson J.L., Iverson B.L., et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20 6 (2002) 597-601
24. 3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem Biophys Res Commun 341 4 (2006) 1164-1171
25. Brossier F., Levy M., Landier A., Lafaye P., and Mock M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 72 11 (2004) 6313-6317
26. Rivera J., Nakouzi A., Abboud N., Revskaya E., Goldman D., Collier R.J., et al. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun 74 7 (2006) 4149-4156
27. Gubbins M.J., Berry J.D., Corbett C.R., Mogridge J., Yuan X.Y., Schmidt L., et al. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol 47 3 (2006) 436-443
28. Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Veremeiko T.A., et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 18 4 (2000) 329-337
29. Ulrich R., Nassal M., Meisel H., and Kruger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 50 (1998) 141-182
30. Milich D.R., and McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234 4782 (1986) 1398-1401
31. Clarke B.E., Newton S.E., Carroll A.R., Francis M.J., Appleyard G., Syred A.D., et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330 6146 (1987) 381-384
32. Birnbaum F., Nassal M., and Hepatitis. B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol 64 7 (1990) 3319-3330
33. Zlotnick A., Cheng N., Conway J.F., Booy F.P., Steven A.C., Stahl S.J., et al. Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry 35 23 (1996) 7412-7421
34. Pumpens P., Borisova G.P., Crowther R.A., and Grens E. Hepatitis B virus core particles as epitope carriers. Intervirology 38 1-2 (1995) 63-74
35. Schodel F, Will H, Milich D. Hybrid hepatitis B virus core/pre-S particles expressed in live attenuated Salmonella for oral immunization. In: Chanock RM, Ginsberg HS, Brown F, Lerner RA, editors. Vaccines. New York: Cold Spring Harbor Laboratory Press; 1991. p. 319-25.
36. Xu J., Dong D., Song X., Ge M., Li G., Fu L., et al. Expression, purification and characterization of the recombinant anthrax protective antigen. Chin J Biotechnol 20 (2004) 652-655
37. Guo Q., Xu J., Dong D., Fu L., and Chen W. Expression and characterization of the recombinant anthrax lethal factor. Acta Microbiol Sinica 44 (2004) 749-751
38. Ulrich R., Koletzki D., Lachmann S., Lundkvist A., Zankl A., Kazaks A., et al. New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J Biotechnol 73 2-3 (1999) 141-153
39. Kratz P.A., Bottcher B., and Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 96 5 (1999) 1915-1920
40. Mihailova M., Boos M., Petrovskis I., Ose V., Skrastina D., Fiedler M., et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 24 20 (2006) 4369-4377
41. Geldmacher A., Skrastina D., Petrovskis I., Borisova G., Berriman J.A., Roseman A.M., et al. An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. Virology 323 1 (2004) 108-119
42. Ivins B.E., Fellows P.F., and Nelson G.O. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 12 10 (1994) 872-874
43. Little S.F., and Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 2 (1986) 509-512
44. Fellows P.F., Linscott M.K., Ivins B.E., Pitt M.L., Rossi C.A., Gibbs P.H., et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19 23-24 (2001) 3241-3247
45. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69 5 (2001) 2888-2893
46. Pumpens P., and Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44 2-3 (2001) 98-114
47. Francis M.J., Hastings G.Z., Brown A.L., Grace K.G., Rowlands D.J., Brown F., et al. Immunological properties of hepatitis B core antigen fusion proteins. Proc Natl Acad Sci USA 87 7 (1990) 2545-2549
48. Pumpens P., and Grens E. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett 442 1 (1999) 1-6
49. Hatton T., Zhou S., and Standring D.N. RNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication. J Virol 66 9 (1992) 5232-5241
50. Manayani D.J., Thomas D., Dryden K.A., Reddy V., Siladi M.E., Marlett J.M., et al. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog 3 10 (2007) e142
51. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 75 8 (2007) 4020-4029